Chemotherapy-Induced Neutropenia (CIN) Treatment Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, Drug, Distribution Channel, Treatment), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Chemotherapy-Induced Neutropenia Treatment Market size was valued at USD 674.62 Million in 2025 and is projected to grow at a 3.6% CAGR from 2026 to 2035, crossing USD 960.85 Million by 2035. The industry revenue for 2026 is estimated at USD 695.27 million.
Get more details on this report
Request Free Sample ReportChemotherapy-Induced Neutropenia (CIN) Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 41.66% share in 2025, supported by high cancer treatment volumes, established supportive oncology care, and routine integration of growth factor therapies into chemotherapy practice.
- Asia Pacific is projected to grow at a 4.1% CAGR as rising oncology caseloads, improving access to cancer care, and broader adoption of supportive therapies increase demand across clinical settings.
Segment Momentum
- Parenteral administration leads with an 88.69% share due to routine injectable G-CSF use in oncology, offering precise dosing, rapid effect, and strong clinical familiarity during chemotherapy cycles.
- Oral therapies are the fastest-growing route as they reduce clinic dependency and improve patient convenience, aligning with outpatient care models and easier adherence across repeated chemotherapy cycles.
Market Expansion Drivers
- Rising global cancer incidence increasing demand for supportive neutropenia management therapies.
- Expanding adoption of biosimilars and G-CSF biologics improving treatment accessibility.
- Increasing shift toward outpatient oncology care reshaping supportive treatment delivery models.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent players in the chemotherapy-induced neutropenia treatment market include Amgen Inc. (United States), Pfizer Inc. (United States), Sandoz Group AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (United States), Coherus BioSciences, Inc. (United States), Biocon Biologics Limited (India), G1 Therapeutics, Inc. (United States), Evive Biotech Co., Ltd. (China).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As cancer diagnoses rise globally, a larger patient pool is entering chemotherapy regimens that carry a meaningful risk of neutropenia, directly driving demand for the chemotherapy-induced neutropenia (CIN) treatment market. In practice, this expands use of supportive therapies as oncologists aim to maintain planned chemotherapy dose intensity, avoid treatment delays, and reduce infection-related complications that can lead to emergency care or hospitalization. The effect is especially visible in treatment settings managing high volumes of myelosuppressive regimens, where preventive and reactive neutropenia management becomes embedded in routine care pathways, reinforcing market demand for G-CSF agents and related supportive interventions.
Expanding adoption of biosimilars and G-CSF biologics improving treatment accessibility
Broader uptake of biosimilars and established G-CSF biologics is reshaping purchasing and prescribing patterns in the chemotherapy-induced neutropenia (CIN) treatment market by lowering cost barriers and widening access to prophylactic care. This is influencing market adoption most clearly in health systems and oncology networks that use formulary decisions, reimbursement controls, and pathway standardization to guide supportive care choices, making neutropenia prevention feasible for a broader share of eligible patients. As affordability improves, providers are more willing to incorporate growth factor support earlier and more consistently, contributing to market size growth through higher treatment penetration rather than reliance on a narrow set of premium products.
Increasing shift toward outpatient oncology care reshaping supportive treatment delivery models
The move toward outpatient oncology care is changing how supportive therapies are selected, scheduled, and administered, strengthening market development in the chemotherapy-induced neutropenia (CIN) treatment market. Providers increasingly favor treatment approaches that fit shorter clinic visits, reduce unplanned returns, and support predictable post-chemotherapy management, which raises the importance of convenient dosing profiles, streamlined administration, and care coordination beyond the hospital setting. This trend influences product preference and service models at the same time, as oncology practices align neutropenia management with ambulatory workflows designed to minimize acute complications while preserving treatment continuity.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing chemotherapy procedures globally | 1.20% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Development of novel CIN therapeutics | 1.30% | Medium term (2–5 yrs) | North America, Asia Pacific | Low | Moderate |
| Expansion of oncology infrastructure in emerging markets | 1.10% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Rising global cancer incidence increasing demand for supportive neutropenia management therapies | 2.00% | High | North America, Europe | High | Near Term |
| Expanding adoption of biosimilars and G-CSF biologics improving treatment accessibility | 1.70% | High | North America, Asia Pacific | High | Mid Term |
| Increasing shift toward outpatient oncology care reshaping supportive treatment delivery models | 1.40% | High | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading position in 2025, accounting for a 41.66% share of the chemotherapy-induced neutropenia (CIN) treatment market. This leadership is underpinned by the region’s high cancer treatment volumes, established use of supportive oncology care, and broad integration of neutropenia management into clinical practice. Market activity is strengthened by the routine use of growth factor therapies alongside chemotherapy protocols, supported by strong provider awareness and treatment access across hospital and specialty care settings.
Asia Pacific is projected to expand at a 4.1% CAGR over the forecast period, with growth in the chemotherapy-induced neutropenia (CIN) treatment market being fueled by rising oncology caseloads and improving access to cancer care across major healthcare systems in the region. Adoption is accelerating as more patients enter formal chemotherapy pathways and supportive care becomes a more consistent part of treatment management. This is translating into stronger demand for CIN therapies in clinical settings where providers are working to reduce treatment delays, infection risk, and chemotherapy-related complications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Guideline-Driven CareGermany emphasizes evidence-based use of granulocyte colony-stimulating factors through established oncology treatment pathways. Hospitals in Germany continue to evaluate therapies that improve patient outcomes while supporting efficient resource utilization.
France 🇫🇷
Hospital Care OptimizationFrance focuses on optimizing supportive cancer care within hospital-based oncology networks. French clinicians increasingly incorporate guideline-aligned neutropenia prevention strategies to minimize treatment interruptions and infection-related complications.
Italy 🇮🇹
Integrated Oncology ManagementItaly continues to strengthen supportive care protocols across regional oncology centers to improve chemotherapy tolerance. Italian healthcare providers are expanding the use of effective neutropenia management approaches aligned with clinical practice recommendations.
Japan 🇯🇵
Precision Supportive CareJapan integrates chemotherapy-induced neutropenia management into standardized cancer care, with strong attention to treatment safety and aging patient populations. Japanese providers increasingly consider convenient dosing schedules that reduce hospital visits.
South Korea 🇰🇷
Advanced Oncology AccessSouth Korea supports wider availability of supportive oncology therapies through expanding cancer treatment infrastructure. Healthcare providers in South Korea are adopting clinically validated options that improve continuity of chemotherapy regimens.
United States 🇺🇸
Oncology Innovation HubThe U.S. prioritizes broader adoption of long-acting supportive care therapies and biosimilars to reduce chemotherapy-related complications. Clinical evidence generation and value-based oncology care continue to shape treatment selection across healthcare providers.
Segment Leadership and Growth Trends
Chemotherapy-Induced Neutropenia (CIN) Treatment Market Share (%), Route of Administration, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportParenteral held an 88.69% share of the chemotherapy-induced neutropenia (CIN) treatment market in 2025, reflecting its established role in supportive oncology care where rapid, reliable drug delivery is critical during chemotherapy cycles. Its leadership is underpinned by routine use of injectable granulocyte colony-stimulating factors in clinical settings, where treatment timing, dose control, and physician familiarity support continued preference for parenteral administration. This entrenched use pattern keeps parenteral products central to the chemotherapy-induced neutropenia (CIN) treatment market despite evolving treatment formats.
Oral is the fastest-growing route in the chemotherapy-induced neutropenia (CIN) treatment market because it aligns with the rising need for more convenient treatment administration outside traditional infusion settings. Growth is being aided by practical demand for reduced clinic dependency and easier patient adherence within cancer care pathways, especially where treatment burden is closely managed over repeated cycles. Compared with parenteral options, oral administration is gaining momentum as care delivery models increasingly value flexibility and patient-friendly supportive care approaches.
Drug Segment Analysis: Biosimilars (Largest & Fastest-Growing Segment)
Biosimilars accounted for a 53.91% share of the chemotherapy-induced neutropenia (CIN) treatment market in 2025, making them the leading drug segment while also maintaining the strongest growth momentum. Their position is aided by expanding acceptance of lower-cost alternatives in oncology supportive care, where treatment access and cost discipline are practical priorities for providers and payers. That same value proposition continues to accelerate uptake in the chemotherapy-induced neutropenia (CIN) treatment market, as biosimilars fit established clinical use patterns while helping healthcare systems manage the recurring burden of neutropenia prevention and treatment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Parenteral, Oral | Parenteral | Oral |
| Drug | Branded Drugs, Biosimilars | Biosimilars | Biosimilars |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | Hospital Pharmacies | Online Pharmacies |
| Treatment | Growth Factors, Antibiotics, Antifungal Agents, Others | Growth Factors | Growth Factors |
Competitive Landscape and Market Positioning
1. Amgen Inc. (United States)
2. Pfizer Inc. (United States)
3. Sandoz Group AG (Switzerland)
4. Teva Pharmaceutical Industries Ltd. (Israel)
5. Viatris Inc. (United States)
6. Coherus BioSciences Inc. (United States)
7. Biocon Biologics Limited (India)
8. G1 Therapeutics Inc. (United States)
9. Evive Biotech Co. Ltd. (China)
The chemotherapy-induced neutropenia (CIN) treatment market is evolving with strong emphasis on supportive oncology care and infection risk management. Advanced therapeutic development is improving patient safety and treatment continuity. Collaborative research efforts are accelerating clinical advancements in supportive care therapies. Regulatory progress and pipeline expansion are further strengthening treatment availability, enhancing outcomes within the chemotherapy-induced neutropenia (CIN) treatment market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Evive Biotech; APOGEPHA Arzneimittel GmbH | Nov-24 | Evive Biotech and APOGEPHA Arzneimittel GmbH announced the availability of Ryzneuta in the German market, expanding commercial access for its long-acting G-CSF therapy. This launch strengthens regional market penetration in Europe and supports broader adoption of chemotherapy-induced neutropenia treatments in oncology care settings. |
| Coherus BioSciences, Inc. | Feb-24 | Coherus BioSciences launched UDENYCA ONBODY, an on-body injector presentation of its pegfilgrastim biosimilar. The product enhances administration convenience and expands the company’s biosimilar oncology portfolio, supporting broader uptake across clinical and home-care settings for chemotherapy-induced neutropenia management. |
| Coherus BioSciences, Inc. | Dec-24 | Coherus BioSciences signed an asset purchase agreement with Intas Pharmaceuticals to divest its UDENYCA franchise for up to USD 558.4 million. The transaction reflects strategic portfolio optimization and impacts competitive positioning within the pegfilgrastim biosimilar segment of chemotherapy-induced neutropenia treatments. |
| Coherus BioSciences, Inc. | Mar-23 | Coherus BioSciences received U.S. FDA approval for UDENYCA (pegfilgrastim-cbqv), a biosimilar indicated to reduce infection risk in chemotherapy-induced neutropenia patients. The approval strengthens the company’s biosimilar oncology portfolio and supports expanded adoption in outpatient and home-care treatment settings. |
| Evive Biotech | Nov-23 | Evive Biotech received U.S. FDA approval for Ryzneuta (efbemalenograstim alfa), a long-acting G-CSF therapy designed to reduce febrile neutropenia in cancer patients undergoing chemotherapy. The approval enhances its clinical positioning in supportive oncology care and expands access to long-acting neutropenia prophylaxis treatments. |
| Mabwell | Jun-25 | Mabwell received approval from China’s NMPA for Mailisheng injection, a long-acting G-CSF therapy used for neutropenia prophylaxis. The approval strengthens its oncology supportive care portfolio and supports commercialization in the rapidly expanding Chinese biosimilars and biologics market. |
| Coherus BioSciences, Inc. | Mar-25 | Coherus BioSciences obtained FDA clearance for Udenyca Onpro, expanding its pegfilgrastim biosimilar offerings with an on-body delivery system. This approval enhances administration flexibility and supports broader adoption in chemotherapy-induced neutropenia prevention across oncology care settings. |
| Teva Pharmaceuticals Industries Ltd.; Alvotech | Jan-25 | Teva Pharmaceuticals and Alvotech received FDA acceptance of the AVT05 biologics license application, a proposed biosimilar to Simponi. This milestone advances their immunology biosimilar pipeline and strengthens their competitive positioning in biologics development and commercialization. |
| X4 Pharmaceuticals | Jan-25 | X4 Pharmaceuticals licensed mavorixafor to Norgine for commercialization across Europe, Australia, and New Zealand. The agreement expands regional market access for the therapy and supports broader global commercialization strategy for rare disease and oncology-adjacent indications. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Chemotherapy-Induced Neutropenia (CIN) Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Chemotherapy-Induced Neutropenia (CIN) Treatment Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much is the chemotherapy-induced neutropenia (CIN) treatment market worth?
What is the expected industry size of chemotherapy-induced neutropenia treatment by 2035?
How is the expansion of outpatient oncology care influencing CIN treatment administration preferences?
Why are biosimilars emerging as both the largest and fastest-growing drug segment in CIN treatment?
Why does the Parenteral route dominate CIN treatment?
What is driving growth in Oral CIN therapies?
Why does North America dominate the chemotherapy-induced neutropenia (CIN) treatment market?
What is supporting CIN treatment market growth in Asia Pacific?
What are the key competitors in the chemotherapy-induced neutropenia treatment landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization